Citadel Advisors
TNGX icon

Citadel Advisors’s Tango Therapeutics TNGX Stock Holding History

Citadel Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.75M Buy
179,423
+27,543
+18% +$383K ﹤0.01% 4835
2025
Q4 		$1.35M Buy
+151,880
New +$1.31M ﹤0.01% 6759
2025
Q3 		– Sell
-55,065
Closed -$282K – 14122
2025
Q2 		$282K Sell
55,065
-51,437
-48% -$127K ﹤0.01% 9948
2025
Q1 		$146K Sell
106,502
-1,520,257
-93% -$3.73M ﹤0.01% 10918
2024
Q4 		$5.03M Sell
1,626,759
-1,067,366
-40% -$4.96M ﹤0.01% 3959
2024
Q3 		$20.7M Buy
2,694,125
+1,462,368
+119% +$14M ﹤0.01% 2014
2024
Q2 		$10.6M Buy
1,231,757
+765,639
+164% +$5.92M ﹤0.01% 2701
2024
Q1 		$3.7M Buy
466,118
+264,303
+131% +$2.83M ﹤0.01% 4441
2023
Q4 		$2M Buy
+201,815
New +$1.75M ﹤0.01% 5349
2023
Q3 		– Sell
-164,986
Closed -$548K – 15111
2023
Q2 		$548K Sell
164,986
-8,076
-5% -$29.1K ﹤0.01% 7748
2023
Q1 		$684K Sell
173,062
-192,323
-53% -$1.12M ﹤0.01% 7634
2022
Q4 		$2.65M Sell
365,385
-112,879
-24% -$794K ﹤0.01% 4961
2022
Q3 		$1.73M Buy
478,264
+64,069
+15% +$274K ﹤0.01% 5860
2022
Q2 		$1.88M Buy
414,195
+16,010
+4% +$96.9K ﹤0.01% 5660
2022
Q1 		$3.02M Sell
398,185
-63,049
-14% -$546K ﹤0.01% 5163
2021
Q4 		$5.05M Buy
461,234
+52,709
+13% +$634K ﹤0.01% 4272
2021
Q3 		$5.28M Buy
408,525
+83,137
+26% +$997K ﹤0.01% 4198
2021
Q2 		$3.69M Buy
325,388
+2,967
+0.9% +$33.3K ﹤0.01% 5113
2021
Q1 		$3.58M Sell
322,421
-36
-0% -$414 ﹤0.01% 5024
2020
Q4 		$3.69M Sell
322,457
-17,861
-5% -$188K ﹤0.01% 4219
2020
Q3 		$3.69M Buy
+340,318
New +$3.48M ﹤0.01% 3622

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Citadel Advisors's TNGX Position: Q1 2026 in Review

Citadel Advisors increased its Tango Therapeutics (TNGX) stake by 18% in Q1 2026, buying an estimated $383K and bringing the position to 179,423 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4835.

Citadel Advisors first reported a position in TNGX in Q3 2020 and has held it in 21 quarters since. The position peaked at $20.7M in Q3 2024. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Citadel Advisors held 179,423 shares of Tango Therapeutics worth $3.75M as of Q1 2026.
  • Citadel Advisors bought 27,543 Tango Therapeutics shares in Q1 2026, an estimated $383K.
  • Tango Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4835 holding.
  • Citadel Advisors first reported a position in Tango Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Citadel Advisors's Tango Therapeutics position peaked at $20.7M in Q3 2024.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.